Directory
>
Eric Valeur
Eric Valeur
VP, Research | Roivant Sciences
Wellesley, Massachusetts, United States
Eric Valeur
Summary
Eric Valeur is a seasoned R&D executive with over 15 years of experience in the biotechnology and pharmaceutical sectors. As the VP of Research at Roivant Sciences, he has been instrumental in pioneering drug discovery approaches, particularly in the integration of small molecules and innovative modalities like RNA-based therapies and PROTACs. His leadership has led to the establishment of the first New Modalities group in the industry, showcasing his ability to drive disruptive innovation. Eric's extensive background includes roles at major companies like AstraZeneca and Novartis, where he has consistently delivered clinical candidates and transformative technologies. He holds a Ph.D. in Organic Chemistry from The University of Edinburgh and an MBA from Imperial College Business School. Eric's passion for innovation is matched by his commitment to improving patient outcomes through scientific advancement.
Eric Valeur
Work Experience
VP, Research at
Roivant Sciences
March 2024 - Present
VP, Head of Drug Discovery at
Roivant Sciences
February 2021 - February 2024
BaseLaunch incubator selection board member at
Roivant Sciences
August 2021 - December 2023
Head of Platform Research at
Flagship VentureLabs
January 2019 - January 2021
Director of New Modalities & Innovation at
AstraZeneca
May 2018 - January 2019
Associate Director, New Modalities Medicinal Chemistry at
AstraZeneca
May 2014 - April 2018
Flagship Pioneering / AstraZeneca Fellow at
Flagship Pioneering
January 2017 - April 2018
Project Leader / Team Leader Medicinal Chemistry at
Novartis
January 2009 - April 2014
Project Leader / Team Leader Medicinal Chemistry at
MERCK ROMANIA SRL
January 2007 - January 2009
Postdoctoral Fellow at
Northern Institute For Cancer Research
February 2006 - January 2007
Eric Valeur
Education
The University of Edinburgh, Doctor Of Philosophy (Ph.D.)
January 2006
Imperial College Business School, Master Of Business Administration (M.B.A.)
January 2015
Ecole Nationale Supérieure de Chimie de Montpellier, Master Of Science (M.Sc.)
January 2002
University of Montpellier, Master Of Science (M.Sc)
January 2002
Frequently Asked Questions about Eric Valeur
What is Eric Valeur email address?
Eric Valeur's primary email address is *******@roivant.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Eric Valeur work for?
Eric Valeur is a VP, Research at Roivant Sciences.
Where Eric Valeur graduated from?
Eric Valeur holds a degree in Organic Chemistry from The University of Edinburgh.
How can I directly contact Eric Valeur?
To contact Eric Valeur directly, you can use the email address *******@roivant.com. Complete contact information is available upon registration with Muraena.
Is Eric Valeur an immigrant?
Yes, Eric Valeur is an immigrant and currently based in United States
Who is Eric Valeur?
Eric Valeur is a seasoned R&D executive with over 15 years of experience in the biotechnology and pharmaceutical sectors. As the VP of Research at Roivant Sciences, he has been instrumental in pioneering drug discovery approaches, particularly in the integration of small molecules and innovative modalities like RNA-based therapies and PROTACs. His leadership has led to the establishment of the first New Modalities group in the industry, showcasing his ability to drive disruptive innovation. Eric's extensive background includes roles at major companies like AstraZeneca and Novartis, where he has consistently delivered clinical candidates and transformative technologies. He holds a Ph.D. in Organic Chemistry from The University of Edinburgh and an MBA from Imperial College Business School. Eric's passion for innovation is matched by his commitment to improving patient outcomes through scientific advancement.
Eric`s contact details
*******@roivant.com
***********@astrazeneca.com
Colleagues
Chief Development Officer
Chief Communications Officer
Chief Financial Officer
Executive Director
VP, Special Projects, Office of CEO
Chief Executive Officer
Vice President, Head of CMC, Small Molecule Development
Board Member
Senior Vice President, Investments
Vice President, Head of CMC, Biologics and Gene Therapies